Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

778
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
778
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.6K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.6K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.5K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.5K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

343
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
343

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Hyaluronan in Keloid and Hypertrophic Scar Pathogenesis and Treatment.

Plastic surgery (Oakville, Ont.)·2026
Same author

Impact of Once-Daily Ivabradine on Average Resting Heart Rate in Patients With Reduced Ejection Fraction With Systolic Dysfunction: A Multicenter, Post-marketing Observational Study.

Cureus·2026
Same author

iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease.

American journal of preventive cardiology·2026
Same author

Disparities in Diagnostic Yield of Genetic Testing in Children and Adolescents With Vascular Malformations and/or Overgrowth: A Single Site Experience.

American journal of medical genetics. Part A·2026
Same author

Multidimensional analysis of the clinical spectrum and symptom burden of unexplained myofascial pain.

Archives of physical medicine and rehabilitation·2026
Same author

Indian Expert Consensus on Hybrid Cardiac Rehabilitation in the Management of Cardiovascular Disease.

Cureus·2026
Same journal

Pleural Toxocariasis Presenting as Eosinophilic Pleural Effusion: A Case Report.

Cureus·2026
Same journal

Left Clavicular Pain Following Splenic Rupture After Colonoscopy: A Variant of Kehr's Sign?

Cureus·2026
Same journal

Severe Polyhydramnios Associated With Antenatal Bartter Syndrome.

Cureus·2026
Same journal

Focal Takotsubo Syndrome Mimicking a Distal Coronary Pathology: A Case Report.

Cureus·2026
Same journal

Metachronous Colorectal Carcinomas and Pancreatic Metastasis in Clinically Suspected Lynch Syndrome: An 18-Year Oncologic Course.

Cureus·2026
Same journal

Regional Blocks in the Era of the Opioid Crisis: Evaluating Their Opioid-Sparing Effect.

Cureus·2026
See all related articles

Related Experiment Video

Updated: Jan 18, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.0K

Optimizing Cardiovascular Outcomes With Bisoprolol: An Evidence-Based Perspective.

Kamal Sharma1, Sunil Sathe2, Bhupen Desai3

  • 1Cardiology, SAL Hospital, Ahmedabad, IND.

Cureus
|September 9, 2025
PubMed
Summary
This summary is machine-generated.

Bisoprolol, a cardio-selective beta-blocker, effectively manages cardiovascular diseases (CVDs), including heart failure with reduced ejection fraction (HFrEF) and angina. It offers proven safety and efficacy, even with comorbidities like chronic kidney disease.

Keywords:
beta blockerbisoprololcardiovascular diseaseheart failurehfref: heart failure with reduced ejection fraction

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.3K

Related Experiment Videos

Last Updated: Jan 18, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.0K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.3K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The cardiovascular continuum describes the progression of cardiovascular diseases (CVDs) towards heart failure (HF) and sudden cardiac death.
  • Beta-blockers (BBs) are crucial in managing conditions across this continuum, from risk factors to established HF.

Purpose of the Study:

  • To provide an evidence-based perspective on the utility of bisoprolol in managing CVDs.
  • To highlight bisoprolol's efficacy and safety in patients with heart failure with reduced ejection fraction (HFrEF) and stable angina.

Main Methods:

  • Review of numerous clinical studies on bisoprolol's efficacy and safety.
  • Inclusion of expert opinions from cardiologists regarding bisoprolol's therapeutic role.
  • Examination of bisoprolol's safety profile in patients with renal and hepatic dysfunction and other comorbidities.

Main Results:

  • Bisoprolol demonstrates high cardio-selectivity, a favorable pharmacokinetic profile, and proven efficacy in reducing cardiac events, arrhythmias, and mortality in HFrEF patients.
  • Bisoprolol is effective in managing stable angina.
  • Bisoprolol exhibits a good safety profile in patients with comorbidities such as chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and diabetes.

Conclusions:

  • Bisoprolol is a valuable therapeutic option for managing HFrEF and stable angina.
  • Expert consensus supports bisoprolol as a first-line therapy for HFrEF and angina, considering patient comorbidities.